10-Q: Applied DNA Sciences Pivots to Biotherapeutics Amid Losses

Applied DNA Sciences reports continued net losses and a going concern warning as it strategically exits non-core businesses to focus on nucleic-acid production for biopharmaceuticals.

Summary

• The company incurred a net loss of $3,984,109 for the three months ended June 30, 2025, compared to a net income of $1,849,501 for the same period in 2024.
• For the nine months ended June 30, 2025, the net loss was $9,988,942, an increase from $3,774,563 in the prior year period.
• Total revenues for the three months ended June 30, 2025, decreased by 35.6% to $304,393 from $472,789 in the prior year.
• Total revenues for the nine months ended June 30, 2025, increased by 19.1% to $1,937,506 from $1,625,863 in the prior year.
• Gross profit for the three months ended June 30, 2025, plummeted by 97.9% to $5,130, with the gross profit percentage falling to 2% from 51% in the prior year.
• Gross profit for the nine months ended June 30, 2025, increased by 30.3% to $1,006,887, with the gross profit percentage rising to 52% from 48% in the prior year.
• Cash and cash equivalents stood at $4,727,677 as of June 30, 2025, down from $5,852,363 at September 30, 2024.
• The company used $9,141,688 in cash from continuing operating activities for the nine months ended June 30, 2025.
• Workforce reductions totaling 39% of headcount and a projected 31% reduction in annual payroll expenses have been implemented since October 2024.
• Two reverse stock splits were effected: 1-for-50 on March 14, 2025, and 1-for-15 on June 2, 2025.
• The company regained compliance with Nasdaq's minimum bid price rule on July 2, 2025, after receiving multiple deficiency notices.

Sentiment

Score: 3

Explanation: The company is undergoing a critical strategic pivot towards a high-growth industry, which is a positive long-term move. However, current financial performance is weak, with significant losses, negative operating cash flow, and a going concern warning. The material weakness in internal controls and past Nasdaq compliance issues add to the risk. While the strategic direction is sound, the immediate financial health and execution risks are substantial.

Positives

• Strategic realignment to focus exclusively on the high-growth Therapeutic DNA Production Services business, exiting less profitable segments.
• Significant workforce reductions (39% headcount, 31% payroll cost reduction) are expected to reduce ongoing operating expenses.
• Nine-month product revenues increased by 31% to $1,239,747, primarily driven by large-scale DNA manufacturing.
• Nine-month gross profit increased by 30% to $1,006,887, with an improved gross profit percentage of 52% due to higher product revenues and favorable product mix.
• Interest income increased significantly by 397% to $168,762 for the nine-month period due to higher cash balances and interest rates.
• Successful regaining of Nasdaq minimum bid price compliance on July 2, 2025, avoiding delisting.

Negatives

• Recurring net losses and negative operating cash flow raise substantial doubt about the company's ability to continue as a going concern.
• Net loss from continuing operations increased to $9,585,822 for the nine months ended June 30, 2025, from $3,502,166 in the prior year.
• Total revenues for the three months ended June 30, 2025, decreased by 35.6%, primarily due to timing of orders in large-scale DNA manufacturing and a decline in textile isotopic testing services.
• Gross profit for the three months ended June 30, 2025, decreased by 98% to $5,130, with the gross profit percentage falling to 2% due to lower revenue volume unable to absorb fixed costs.
• Selling, general and administrative expenses increased by 11% for the three-month period, primarily due to a $450,000 accrual for the former CEO's separation agreement.
• Significant non-cash deemed dividends related to warrant modifications totaled $54,326,896 for the nine-month period, impacting net loss attributable to common stockholders.
• Identified a material weakness in internal control over financial reporting related to the preparation and review of inputs for fair value calculations, specifically warrant modifications.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring net losses and negative operating cash flow.
• Need for additional financing, which may require the issuance of additional shares of common stock, preferred stock, or other debt/equity securities, leading to further stockholder dilution.
• The business strategy concentrating on Therapeutic DNA Production Services is unproven, and demand for these services may not materialize as expected.
• Dependence on regulatory approval and compliance for Therapeutic DNA Production Services, which is a substantial part of the new business strategy.
• The 2025 Reverse Stock Splits may decrease the liquidity of common stock, and the resulting market price may not attract new investors, including institutional investors.
• Risk of delisting from Nasdaq if the company fails to comply with the Bid Price Rule or other listing requirements in the future.
• Inherent uncertainties of product development based on new and unproven technologies, and the risks associated with clinical testing and regulatory approval processes.
• Volatility of, and decline in, the company's stock price.

Future Outlook

The company is focusing its resources on the development and commercialization of its Therapeutic DNA Production Services business, including LineaDNA, LineaRNAP, and LineaIVT. It aims to capitalize on the rapid growth of DNA needed for advanced biotherapeutics and the growing demand for materials used in mRNA-based drug discovery and manufacturing. The company expects to achieve ISO 13485 certification in Q1 FY2026 and plans for GMP drug substance availability for LineaDNA and full GMP manufacturing of LineaRNAP in 2H CY2026. It also intends to explore technology out-licensing models and collaborations within the biotherapeutic manufacturing marketplace.

Management Comments

• Management believes its current manufacturing capabilities are sufficient to support near-term customer demand for LineaDNA and LineaRNAP.
• The company's actions are intended to reduce its operating costs and concentrate resources on the development and commercialization of its Therapeutic DNA Production Services business.
• Management believes its technology solutions are differentiated in the market and offer compelling commercial advantages over legacy technologies.

Industry Context

Applied DNA Sciences is strategically pivoting to align with the rapid growth in the biopharmaceutical and diagnostics industries, particularly in gene therapies, adoptive cell therapies, mRNA therapeutics, DNA vaccines, and in vitro diagnostics (IVD). The company's focus on cell-free DNA and RNA production (LineaDNA, LineaRNAP, LineaIVT) positions it to address the limitations of traditional plasmid-based DNA manufacturing, which is complex, costly, and time-consuming. The increasing number of gene, cell, and RNA therapies in development (4,418 as of Q1 2025) and mRNA therapies (over 450 as of Q3 2024) indicates a substantial and growing market opportunity for the company's specialized nucleic-acid production solutions. The company's emphasis on speed, scalability, purity, simplicity, and flexibility aims to differentiate it from legacy technologies.

Comparison to Industry Standards

• LineaDNA is presented as an alternative to plasmid-based DNA manufacturing, which has been the standard for 40 years. The company highlights LineaDNA's advantages in speed (hours vs. days/weeks), scalability (bench-top instruments, minimal footprint), purity (no unwanted DNA sequences like plasmid backbone or antibiotic resistance genes), simplicity (fewer ingredients, no living cells or complex fermentation), and flexibility (chemical modification, ssDNA/cirDNA production, complex sequences like ITRs and poly(A) tails).
• LineaRNAP is compared to conventional WT-T7 RNAP, with company data showing higher mRNA yields, lower dsRNA contamination, and higher mRNA integrity when used in conventional IVT systems.
• The LineaIVT system is stated to reduce dsRNA contamination by 10x to 50x compared to conventional systems for mRNA manufacture, while achieving equivalent or greater target mRNA yields.
• The company's GMP manufacturing site for LineaDNA is capable of producing up to 10 grams annually at single shift capacity, with additional RUO capacity of over 15 grams per year. This capacity is deemed sufficient for near-term customer demand.
• LineaRNAP manufacturing is performed by Alphazyme, LLC, an ISO 13485 quality system certified CDMO, which the company believes is sufficient for early-stage clinical use of the enzyme.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from past and potential future capital raises and warrant exercises. Experience volatility and decline in stock price. The going concern warning indicates high financial risk. Strategic pivot could offer long-term upside if successful.
• **Employees:** Experienced significant workforce reductions (39% total headcount reduction) as part of strategic restructuring, leading to job losses but potentially a more focused and stable future for remaining employees.
• **Customers:** Those in the Therapeutic DNA Production Services segment may benefit from increased focus and investment in these solutions. Customers in the exited DNA Tagging and Security and MDx Testing Services segments will need to find alternative providers.
• **Creditors:** The going concern warning and recurring losses indicate elevated credit risk.
• **Management:** New CEO Judith Murrah has taken a voluntary 15% salary reduction, demonstrating commitment to cost control during the transition.

Next Steps

• Continue to strategically exit contracts related to the DNA Tagging and Security Products and Services business.
• Further develop, commercialize, and drive customer adoption of LineaDNA, LineaRNAP, and LineaIVT technology solutions.
• Pursue ISO 13485 certification, expected to be completed in FY2026 Q1.
• Plan for GMP drug substance availability for LineaDNA in 2H CY2026.
• Explore full GMP manufacturing of LineaRNAP with CDMOs during FY2026, with planned availability in 2H CY2026.
• Work with current or other third-party CDMOs to continue reducing LineaRNAP manufacturing unit costs.
• Potentially explore technology out-licensing models for some or all technology solutions in the future.
• Seek collaborations both upstream and downstream within the biotherapeutic manufacturing marketplace.
• Remediate the identified material weakness in internal control over financial reporting by ensuring all inputs in fair value calculations agree to underlying documents and are properly reviewed.

Key Dates

Recommendation

Applied DNA Sciences is undergoing a critical strategic transformation, exiting unprofitable segments to focus on the high-growth biopharmaceutical and diagnostics industries. While this pivot is strategically sound and addresses market opportunities, the company currently faces significant financial challenges, including recurring net losses, negative operating cash flow, and a 'going concern' warning. The stock has experienced extreme volatility and dilution due to multiple reverse stock splits and warrant adjustments. The identified material weakness in internal controls adds to the operational risk. Given the high uncertainty surrounding the successful execution of the new strategy and the precarious financial position, a 'hold' recommendation is appropriate. Investors should monitor progress on revenue generation from the new core business, sustained cost reductions, and the remediation of internal control weaknesses before considering further investment. The long-term potential is there, but the short-to-medium term risks are substantial.

Keywords

Biotechnology, DNA production, RNA production, Therapeutic DNA, Gene therapy, mRNA therapeutics, Diagnostics, LineaDNA, LineaRNAP, LineaIVT, SEC filing, 10-Q, Biopharmaceutical, Molecular diagnostics, Reverse stock split, Nasdaq compliance, Going concern